Enliven Therapeutics’ leukemia drug shows promise in new study

Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug growth, enterprise, Wall Avenue, and biotechnology. He’s additionally a co-host of the weekly biotech podcast The Readout Loud and writer of the publication Adam’s Biotech Scorecard. You’ll be able to attain Adam on Sign at stataf.54.

A focused drug from Enliven Therapeutics induced molecular responses in almost half of sufferers with superior leukemia, together with increased response charges in sufferers handled at an earlier stage of their illness.

The up to date early-stage research outcomes reported Thursday for the Enliven drug, ELVN-001, evaluate favorably to a present blockbuster drugs offered by Novartis and an upstart experimental drug lately purchased by Merck.

At 24 weeks, an 80 mg, once-daily dose of ELVN-001 achieved a significant molecular response in 48% of sufferers with continual myeloid leukemia, or CML, a slow-growing most cancers that begins in myeloid cells.